A Phase 1B, Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Q203 When Administered Orally to Healthy Adult Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Apr 2018
At a glance
- Drugs Q 203 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- Sponsors Qurient Co
- 10 Apr 2018 Planned primary completion date changed from 1 Dec 2017 to 1 May 2018.
- 10 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 09 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2017.